Out of the 13,568 individuals diagnosed with malignant melanoma, 145 individuals underwent PD-1i therapy, while another 212 received treatment with cytotoxic T-lymphocyte-associated protein-4 inhibitor (CTLA-4i) (53). The gene discussed is CTLA4; the disease is melanoma.